Statement on extension of TRIPS waiver for COVID-19 diagnostics & therapeutics, 9 January 2023

South Centre Statement on the extension of the TRIPS waiver for diagnostics and therapeutics for COVID-19

Developing countries should consider options that can be implemented now to deal with IP barriers to expand production and access to COVID-19 therapeutics and diagnostics, while the so far elusive decision on whether to extend a TRIPS waiver to cover these products is taken by WTO.

Download statement:

South Centre Statement on the extension of the TRIPS waiver for diagnostics and therapeutics for COVID-19


This article was tagged: , , , , , , , , , , , , , , ,
0

Your Cart